.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

The OncLive Insider app is live!
CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Changing Therapeutic Landscape in ALL, CLL, and NHL

EP. 1: Introduction: Treating ALL in Adult Patients

January 22nd 2014

EP. 2: Novel Therapies for Patients Ph-Negative ALL

January 22nd 2014

EP. 3: Emerging Strategies in the Treatment of ALL

January 22nd 2014

EP. 4: Surrogate Endpoints for New Drug Discovery in ALL

January 22nd 2014

EP. 5: Efficacy and Future Role of Ibrutinib in CLL and MCL

January 22nd 2014

EP. 6: Combining and Sequencing New Agents in CLL

January 22nd 2014

EP. 7: Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas

January 22nd 2014

EP. 8: PI3K Inhibition in Hematologic Malignancies

January 22nd 2014

EP. 9: Brentuximab Vedotin in Diffuse Large B-cell Lymphoma

January 22nd 2014

EP. 10: Combination Therapy in Large Cell Lymphomas

January 22nd 2014

EP. 11: Changing Therapeutic Landscape in ALL, CLL, and NHL

January 22nd 2014